Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.52 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.52 |
| ▸ | INSR | P06213 | 10/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281988 | 1.00 | IGF1R (0.60) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL4284764 | 0.94 | IGF1R (0.61) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL4282762 | 0.91 | IGF1R (0.64) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL4278085 | 0.90 | IGF1R (0.61) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL12640221 | 0.89 | IGF1R (0.62) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL1892304 | 0.89 | IGF1R (0.59) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL1887065 | 0.89 | IGF1R (0.59) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL1887061 | 0.89 | IGF1R (0.59) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL1373476 | 0.89 | IGF1R (0.60) | IGF1RNTRK1NTRK3NTRK2INSR | |
| SCHEMBL1370640 | 0.89 | IGF1R (0.60) | IGF1RNTRK1NTRK3NTRK2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999131-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-23 | — | — | EP | claimed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | claimed |
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| EP-1999131-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-23 | — | — | EP | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | MAP3K19, CDK2, MAP3K1 | IGF1R 530/4885NTRK1 1106/4885NTRK3 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.